中药康艾注射液辅助化疗治疗中国乳腺癌患者的Meta分析
The Traditional Chinese Medicine Kangai Injection as an Adjuvant Method in Combination with Chemotherapy for the Treatment of Breast Cancer in Chinese Patients: A Meta-Analysis.
作者信息
Xue Jing-Xian, Zhu Zhi-Yuan, Bian Wei-He, Yao Chang
机构信息
Department of Breast Diseases, First Clinical Medical School, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing, Jiangsu 210023, China.
Department of Breast Diseases, Jiangsu Province Hospital of Traditional Chinese Medicine/Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, No. 155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu 210000, China.
出版信息
Evid Based Complement Alternat Med. 2018 Apr 18;2018:6305645. doi: 10.1155/2018/6305645. eCollection 2018.
OBJECTIVE
The traditional Chinese medicine Kangai injection as an adjuvant method in combination with chemotherapy has been widely used for treating breast cancer in clinical practice in China. This study systematically reviewed the clinical effect and safety of traditional Chinese medicine Kangai injection as an adjuvant method in combination with chemotherapy for treating Chinese patients with breast cancer.
METHODS
Seven databases were searched in this study, namely, PubMed, the Cochrane Library, Embase, CNKI, Sino Med, VIP, and Wanfang Data. The timeframe of retrieval was set from the founding date of each database to November 1, 2017.
RESULTS
Fifteen papers were included in this study. The quality of all the studies included was low. All the studies were carried out among the Chinese population. Meta-analyses showed that, compared with single-use chemotherapy, using a Kangai injection combined with chemotherapy to treat Chinese breast cancer patient can increase the total effective rate [RR = 1.15, 95% CI (1.01, 1.32), and = 0.033], improve the quality of life [RR = 1.30, 95% CI (1.14, 1.48), and ≤ 0.001], decrease the incidence of weight loss [RR = 0.49, 95% CI (0.32, 0.77), and = 0.002], decrease WBC count [RR = 0.78, 95% CI (0.68, 0.89), and ≤ 0.001], decrease incidence of renal and liver dysfunction [RR = 0.58, 95% CI (0.46, 0.73), and ≤ 0.001], and decrease cardiac dysfunction [RR = 0.41, 95% CI (0.18, 0.94), and = 0.035]. For the incidence of gastrointestinal adverse reactions [RR = 0.89, 95% CI (0.65, 1.21), and = 0.452], decreased platelet count [RR=0.49, 95% CI (0.18, 1.30), and = 0.150], and alopecia [RR = 1.01, 95% CI (0.89, 1.14), and = 0.879], these two groups showed no statistically significant differences.
CONCLUSION
Kangai injection as an adjuvant method in combination with chemotherapy for treating Chinese breast cancer patients can improve their life quality and physical conditions and reduce the adverse reactions that result from chemotherapy. However, the present conclusion is only suitable for the Chinese population. The long-term, high-quality researches are required to further verify the above conclusions.
目的
中药康艾注射液作为辅助手段联合化疗在中国临床实践中已被广泛用于治疗乳腺癌。本研究系统评价了中药康艾注射液作为辅助手段联合化疗治疗中国乳腺癌患者的临床疗效和安全性。
方法
本研究检索了7个数据库，即PubMed、考克兰图书馆、Embase、中国知网、中国生物医学文献数据库、维普资讯和万方数据。检索时间范围设定为从每个数据库建库日期至2017年11月1日。
结果
本研究纳入15篇论文。所有纳入研究的质量均较低。所有研究均在中国人群中开展。Meta分析显示，与单纯化疗相比，使用康艾注射液联合化疗治疗中国乳腺癌患者可提高总有效率[RR = 1.15，95%CI（1.01，1.32）,P = 0.033]，改善生活质量[RR = 1.30，95%CI（1.14，1.48）,P≤0.001]，降低体重减轻发生率[RR = 0.49，95%CI（0.32，0.77）,P = 0.002]，降低白细胞计数[RR = 0.78，95%CI（0.68，0.89）,P≤0.001]，降低肝肾功能障碍发生率[RR = 0.58，95%CI（0.46，0.73）,P≤0.001]，降低心脏功能障碍发生率[RR = 0.41，95%CI（0.18，0.94）,P = 0.035]。对于胃肠道不良反应发生率[RR = 0.89，95%CI（0.65，1.21）,P = 0.452]、血小板计数降低[RR = 0.49，95%CI（0.18，1.30）,P = 0.150]和脱发[RR = 1.01，95%CI（0.89，1.14）,P = 0.879]，两组间差异无统计学意义。
结论
康艾注射液作为辅助手段联合化疗治疗中国乳腺癌患者可改善其生活质量和身体状况，并减少化疗所致不良反应。然而，目前的结论仅适用于中国人群。需要长期、高质量的研究进一步验证上述结论。
Zotero 插件